Upfront maintenance with anti-vascular versus PARP inhibitors in advanced ovarian cancer: A cost-effective analysis

Journal article

Peer reviewed

M.T. Richardson, D.S. Kapp, J.E. Chan, S.Y. Liang, A.K. Mann, B.J. Monk, T.J. Herzog, D.S. Lakomy, R.L. Coleman and J.K. Chan

Gynecologic oncology, Vol.159, pp.21-21

10/2020

Metrics

1 Record Views

Title: Upfront maintenance with anti-vascular versus PARP inhibitors in advanced ovarian cancer: A cost-effective analysis
Creators: M.T. Richardson - Stanford University School of Medicine
D.S. Kapp - Stanford University
J.E. Chan - Stanford University School of Medicine
S.Y. Liang - Palo Alto Institute
A.K. Mann - Palo Alto Institute
B.J. Monk - The US Oncology Network
T.J. Herzog - UC Health Barrett Cancer Center, Cincinnati, OH, USA
D.S. Lakomy - Dartmouth College
R.L. Coleman - The University of Texas MD Anderson Cancer Center, Houston, TX, USA
J.K. Chan - California Pacific and Palo Alto Medical Foundation/Sutter Health Research Institute, San Francisco, CA, USA
Publication Details: Gynecologic oncology, Vol.159, pp.21-21
Publisher: Elsevier Inc
Identifiers: 991005969167602656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article